VGH Solutions Feels Pain In US Review For Basing OTC Device Ad Claims On Canada’s Approval
Executive Summary
NAD advises VGH Solutions to pull pain relief claims and statements that am OTC device with FDA 510(k) clearance treats conditions including neuropathy. The firm offered studies and a Health Canada statement listing indications for the device to support claims not part of the US approved indication.
You may also be interested in...
NAD: Firm's Laser Cap Hair-Regrowth Claims Not Supported, Despite FDA Clearance
The Capillus82 Hair Regrowth Laser Cap may be "substantially equivalent" to the manufacturer's Capillus272 Pro device, based on FDA's 510(k) clearance, but NAD says hair-growth clinical findings from that "predicate" device cannot serve to substantiate claims for the untested Capillus82. The case illustrates complexities in the medical device segment, which increasingly is of interest to cosmetics companies.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.